NZ623808A - 7-{ (3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl} -6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal - Google Patents

7-{ (3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl} -6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal Download PDF

Info

Publication number
NZ623808A
NZ623808A NZ623808A NZ62380812A NZ623808A NZ 623808 A NZ623808 A NZ 623808A NZ 623808 A NZ623808 A NZ 623808A NZ 62380812 A NZ62380812 A NZ 62380812A NZ 623808 A NZ623808 A NZ 623808A
Authority
NZ
New Zealand
Prior art keywords
crystals
hydrochloride salt
compound
mixture
fluoroethyl
Prior art date
Application number
NZ623808A
Other languages
English (en)
Inventor
Ichiro Araya
Akinori Goto
Wataru Minagawa
Keiko Funada
Muneki Nagao
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of NZ623808A publication Critical patent/NZ623808A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ623808A 2011-11-10 2012-11-09 7-{ (3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl} -6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal NZ623808A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011246209 2011-11-10
JP2012071739 2012-03-27
PCT/JP2012/007195 WO2013069297A1 (fr) 2011-11-10 2012-11-09 Cristal de l'acide 7-{(3s,4s)-3-[(cyclopropylamino)méthyl]-4- fluoropyrrolidin-1-yl}-6-fluoro-1-(2-fluoroéthyl)-8-méthoxy-4-oxo-1,4- dihydroquinoléine-3-carboxylique

Publications (1)

Publication Number Publication Date
NZ623808A true NZ623808A (en) 2015-07-31

Family

ID=48289529

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ623808A NZ623808A (en) 2011-11-10 2012-11-09 7-{ (3s,4s)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl} -6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal

Country Status (16)

Country Link
US (3) US9090587B2 (fr)
EP (2) EP3112359B1 (fr)
JP (4) JP5871948B2 (fr)
KR (2) KR20140098074A (fr)
CN (2) CN103930414B (fr)
AU (1) AU2016273899B2 (fr)
BR (1) BR112014010765B1 (fr)
CA (1) CA2855022C (fr)
ES (2) ES2747303T3 (fr)
IN (1) IN2014DN03277A (fr)
NZ (1) NZ623808A (fr)
RU (2) RU2017109814A (fr)
SA (1) SA112330992B1 (fr)
SG (2) SG11201401817TA (fr)
TW (1) TWI547492B (fr)
WO (1) WO2013069297A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
JP6349306B2 (ja) * 2013-04-25 2018-06-27 杏林製薬株式会社 錠剤
CN105338982B (zh) 2013-04-25 2017-10-10 杏林制药株式会社 固体药用组合物
JP5700740B1 (ja) * 2013-04-25 2015-04-15 杏林製薬株式会社 固形医薬組成物
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2016063542A1 (fr) * 2014-10-23 2016-04-28 杏林製薬株式会社 Composition pharmaceutique solide
US20170246160A1 (en) * 2014-10-23 2017-08-31 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
EA201791995A1 (ru) * 2015-03-13 2017-12-29 Керин Фармасьютикал Ко., Лтд. Средство для лечения респираторной инфекции
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
WO2016195021A1 (fr) 2015-06-02 2016-12-08 杏林製薬株式会社 Formulation liquide aqueuse
EP3305295A4 (fr) * 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. Médicament aqueux
US20210137913A1 (en) 2017-06-16 2021-05-13 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
TW202415375A (zh) * 2017-06-16 2024-04-16 日商杏林製藥股份有限公司 吸入性肺炎、肺化膿症或肺膿瘍之治療劑
WO2023032083A1 (fr) 2021-09-01 2023-03-09 株式会社日立ハイテクサイエンス Dispositif à faisceau de particules chargées et procédé de réglage du dispositif à faisceau de particules chargées

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA944369B (en) * 1993-08-27 1995-02-13 Hokuriku Seuyaku Co Ltd 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
CN1158846A (zh) * 1995-05-09 1997-09-10 昆山市康壮达兽药厂 盐酸氟哌酸的合成工艺
US20030119060A1 (en) 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003076428A1 (fr) * 2002-03-08 2003-09-18 Daiichi Pharmaceutical Co., Ltd. Derive d'acide quinolone-carboxylique
WO2005026147A1 (fr) 2003-09-10 2005-03-24 Kyorin Pharmaceutical Co., Ltd. Derive d'acide quinolonecarboxylique 7-(4-substitue 3-cyclopropylaminomethyl-1-pyrrolidinyle)
CN101003540A (zh) * 2006-01-18 2007-07-25 广州白云山制药股份有限公司广州白云山制药总厂 一种抗感染化合物和用途
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي

Also Published As

Publication number Publication date
EP3112359A1 (fr) 2017-01-04
SA112330992B1 (ar) 2015-09-13
WO2013069297A1 (fr) 2013-05-16
SG10201608167UA (en) 2016-11-29
EP3112359B1 (fr) 2019-08-21
JP2016027045A (ja) 2016-02-18
RU2017109814A3 (fr) 2020-04-08
RU2017109814A (ru) 2019-01-23
US9328089B2 (en) 2016-05-03
TW201332991A (zh) 2013-08-16
CN103930414A (zh) 2014-07-16
BR112014010765A2 (pt) 2017-06-13
JP6514069B2 (ja) 2019-05-15
CA2855022A1 (fr) 2013-05-16
IN2014DN03277A (fr) 2015-05-22
AU2012337206A1 (en) 2014-05-22
JP6349435B2 (ja) 2018-06-27
CA2855022C (fr) 2019-05-07
KR20190065456A (ko) 2019-06-11
AU2016273899B2 (en) 2017-07-27
CN104945375B (zh) 2017-07-04
JP2018158949A (ja) 2018-10-11
SG11201401817TA (en) 2014-08-28
USRE47785E1 (en) 2019-12-31
CN103930414B (zh) 2016-01-20
JP6818719B2 (ja) 2021-01-20
AU2012337206B2 (en) 2016-09-15
US20140288310A1 (en) 2014-09-25
KR20140098074A (ko) 2014-08-07
BR112014010765B1 (pt) 2020-07-14
RU2014123567A (ru) 2015-12-20
US9090587B2 (en) 2015-07-28
EP2778159A1 (fr) 2014-09-17
ES2747303T3 (es) 2020-03-10
US20150284361A1 (en) 2015-10-08
TWI547492B (zh) 2016-09-01
EP2778159A4 (fr) 2015-06-03
JP2017160243A (ja) 2017-09-14
CN104945375A (zh) 2015-09-30
KR102162208B1 (ko) 2020-10-06
JP5871948B2 (ja) 2016-03-01
EP2778159B1 (fr) 2017-03-01
ES2621664T3 (es) 2017-07-04
AU2012337206A8 (en) 2016-09-22
JPWO2013069297A1 (ja) 2015-04-02
RU2615509C2 (ru) 2017-04-05
AU2016273899A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
USRE47785E1 (en) 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
RU2728827C2 (ru) Кристаллическая форма ингибитора тирозинкиназы брутона и способ её получения
ES2594252T3 (es) Compuesto de quinolona y composición farmacéutica
CA2965716C (fr) Forme cristalline de bisulfate inhibiteur de kinase jak et procede de preparation correspondant
AU2012337206B8 (en) 7-{(3S,4S)-3-[(cyclopropylamino)methyl]-4-fluoropyrrolidine-1-yl}-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid crystal
MX2014005007A (es) Cristal del acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluorop irrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidr oquinolin-3-carboxilico.
ES2861062T3 (es) Procedimiento de purificación de un derivado de benzopirano, forma cristalina del mismo, y procedimiento de preparación de la forma cristalina

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2017 BY CPA GLOBAL

Effective date: 20160930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2018 BY CPA GLOBAL

Effective date: 20170929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2019 BY CPA GLOBAL

Effective date: 20180927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2020 BY CPA GLOBAL

Effective date: 20191003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 NOV 2021 BY CPA GLOBAL

Effective date: 20201001

LAPS Patent lapsed